SLC5A2 and type 2 diabetes mellitus: In obese patients with T2D without other comorbidities, while both agents promote weight loss, GLP-1RA may be preferred as the first agent, due to greater weight loss at the upper range than SGLT2 inhibitors, particularly with the longer acting liraglutide and semaglutide78.